UroGen Pharma announced the FDA has accepted its New Drug Application (NDA) for UGN-103, an investigational treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The FDA set a Prescription Drug User Fee Act (PDUFA) target date of June 14, 2027, for review. UGN-103 builds on UroGen's existing drug ZUSDURI, using proprietary RTGel technology for sustained drug release, and showed promising results in the Phase 3 UTOPIA trial with a 77.8% complete response rate at three months. This acceptance marks a significant step toward potentially offering a new, non-surgical treatment option for patients with this recurrent bladder cancer type.
UroGen's FDA acceptance of the NDA for UGN-103 provides context for health sector activity. For readers following health stocks, 73 of 150 US health-sector stocks on Pluang rose while 47 fell. Notable movers include BFLY at USD 7.38 (+1.86%), ELAN at USD 23.97 (+1.78%), and LQDA at USD 33.76 (-1.72%) as of Oct 19, 2026 18:01 WIB.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
